Evolva to participate in European research project Donnerstag, 05. Dezember 2013 - 07:01

Reinach, Switzerland, 5 December 2013 – Evolva Holding SA (SIX: EVE) today announced that it will participate in the EU-funded PROMYS research project. The project has a duration of four years and a total EU funding of EUR 7.2 million (CHF 8.9 million), of which Evolva’s share is 9.8%. The project is the latest of a series of EU collaborations that Evolva has been awarded with partners.

The PROMYS project is part of the European Commission’s 7^th Framework Programme for Research (“FP7”). The project’s goal is to implement a novel platform technology termed ligand responsive regulation and selection systems. This technology will be applied to deliver increased fermentation yields by continuously selecting for high yielding cell factories within a fermentation population. The other participants in the PROMYS project are the Technical University of Denmark and the universities of Darmstadt (Germany), Groningen (Netherlands) and Warwick (UK). Apart from Evolva, companies from Spain (Bacmine S.L.) and Denmark (Biosynthia ApS) are participating.

Evolva’s role in the project will be to construct a yeast that is able to produce high yields of a taste modulating ingredient. The biosynthetic pathway to this ingredient will be used in other parts of the project. The ingredient is also commercially attractive in its own right. Apart from the grant received, Evolva will retain the right to commercialise the fermentation-derived product.

Neil Goldsmith, Evolva’s CEO, commented, “PROMYS clearly shows the European Union’s commitment to synthetic biology as an innovative, sustainable alternative production method. The fact that the PROMYS application came in 1^st among 131 in the selection procedure, confirms the participants’ leading position in this space. We are looking forward to working with academia and corporates in this ground-breaking project.”

Evolva is involved in a number of collaborative research projects, partially funded by the EU or other institutions, and is highly committed to the generation and sharing of knowledge in our scientific area. In total, Evolva has dedicated some 5 FTEs to such projects, or close to 6% of the R&D staff. Additional information on the key projects is available on Evolva’s website.

- ends -

Overview of Evolva’s publicly funded projects (more details on Evolva's website)

About Evolva

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, vanilla, saffron and resveratrol. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com.

Contact Details

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.